1
|
Tuning of CD40–CD154 Interactions in Human B-Lymphocyte Activation: A Broad Array of In Vitro Models for a Complex In Vivo Situation. Arch Immunol Ther Exp (Warsz) 2011; 59:25-40. [DOI: 10.1007/s00005-010-0108-8] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2010] [Accepted: 08/19/2010] [Indexed: 12/13/2022]
|
2
|
Wang S, Wang S, Yang T, Zhu F, Zhu J, Huang Y, Wu L, Chen L, Xu Z. CD40L-mediated inhibition of NF-kappaB in CA46 Burkitt lymphoma cells promotes apoptosis. Leuk Lymphoma 2009; 49:1792-9. [DOI: 10.1080/10428190802216723] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
3
|
Stojanovic T, Scheele L, Wagner AH, Middel P, Bedke J, Lautenschläger I, Leister I, Panzner S, Hecker M. STAT-1 decoy oligonucleotide improves microcirculation and reduces acute rejection in allogeneic rat small bowel transplants. Gene Ther 2007; 14:883-90. [PMID: 17361215 DOI: 10.1038/sj.gt.3302931] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
During acute rejection leukocyte-endothelial cell interaction fuelled by costimulatory molecules such as the CD40/CD154 receptor/ligand dyad disrupts microcirculation of the small bowel. Downregulating endothelial CD40 expression by employing a decoy oligonucleotide (dODN) neutralizing the transcription factor signal transducer and activator of transcription-1 (STAT-1) may protect the graft. Therefore allogenic small bowel transplantation was performed in the Brown Norway to Lewis rat model. Graft vessels were pretreated with STAT-1 dODN, mutant control ODN (20 microM) or vehicle (n=8). CD40 antisense ODN and scrambled control ODN-treated transplants served as target control (n=3 each). Intravital microscopy, histology, immunohistochemistry and Western blot analyses were performed 7 days later. Functional capillary density, red blood cell velocity and perfusion index in STAT-1 dODN and CD40 antisense ODN-treated transplants were improved whereas stasis index was reduced. Leukocyte-endothelial cell interaction showed no difference. Histological parameters of rejection, infiltrating CD3-positive cells and apoptotic bodies were also reduced in STAT-1 dODN and CD40 antisense ODN-treated transplants 7 days post-transplantation. CD40 protein abundance was reduced to less than 10% of control in STAT-1 dODN-treated grafts. STAT-1 dODN blockade of CD40 expression improves mucosal perfusion, reduces graft rejection, T-cell infiltration and apoptosis in rat small bowel allografts during acute rejection.
Collapse
MESH Headings
- Acute Disease
- Animals
- Apoptosis
- Blood Flow Velocity
- Blotting, Western
- CD40 Antigens/analysis
- CD40 Antigens/genetics
- CD40 Antigens/metabolism
- Down-Regulation
- Endothelium, Vascular/immunology
- Genetic Engineering
- Genetic Therapy/methods
- Graft Rejection/prevention & control
- Immunohistochemistry
- Intestinal Mucosa/blood supply
- Intestinal Mucosa/immunology
- Intestine, Small/blood supply
- Intestine, Small/immunology
- Intestine, Small/transplantation
- Liposomes/administration & dosage
- Male
- Microcirculation
- Models, Animal
- Mutation
- Oligonucleotides, Antisense/administration & dosage
- Oligonucleotides, Antisense/genetics
- Random Allocation
- Rats
- Rats, Inbred BN
- Rats, Inbred Lew
- STAT1 Transcription Factor/analysis
- STAT1 Transcription Factor/antagonists & inhibitors
- STAT1 Transcription Factor/genetics
- Transplantation, Homologous
Collapse
Affiliation(s)
- T Stojanovic
- Department of Heart, Thoracic and Vascular Surgery, University Hospital Göttingen, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Néron S, Racine C, Roy A, Guérin M. Differential responses of human B-lymphocyte subpopulations to graded levels of CD40-CD154 interaction. Immunology 2006; 116:454-63. [PMID: 16313359 PMCID: PMC1802436 DOI: 10.1111/j.1365-2567.2005.02244.x] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
Naïve and memory B-lymphocyte populations are activated by CD154 interaction through cell-surface CD40. This interaction plays an important role in the regulation of the humoral immune response, and increasing evidence indicates that fine variation in CD40 binding influences B lymphocytes, macrophages and dendritic cells in murine models. Here we have investigated whether and how variations in the intensity of the CD40-CD154 interaction could contribute to differential regulation of human B-lymphocyte populations. Proliferation and differentiation of B lymphocytes were monitored in response to graded levels of CD40 stimulation in the presence of interleukin (IL)-2, IL-4 and IL-10. Our results show that the level of CD154 binding to CD40 on B lymphocytes can directly influence the evolution of CD19(+) CD27(-) and CD19(+) CD27(+) cell populations. Furthermore, proliferation, global expansion of CD19(+) cells and emergence of CD38(++) CD138(+) cells, as well as immunoglobulin G (IgG) and IgM secretion, were affected by the level of exposure of B lymphocytes to CD154. These results suggest that the CD40-CD154 interaction is more like a rheostat than an on/off switch, and its variation of intensity may play a role in the regulation of B-lymphocyte activation following the primary and/or secondary humoral immune response.
Collapse
Affiliation(s)
- Sonia Néron
- Héma-Québec, Ingénierie Cellulaire, Recherche et Développement, Sainte-foy, Canada.
| | | | | | | |
Collapse
|
5
|
Runarsson G, Liu A, Mahshid Y, Feltenmark S, Pettersson A, Klein E, Björkholm M, Claesson HE. Leukotriene B4 plays a pivotal role in CD40-dependent activation of chronic B lymphocytic leukemia cells. Blood 2005; 105:1274-9. [PMID: 15454480 DOI: 10.1182/blood-2004-07-2546] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
AbstractBiosynthesis of leukotrienes (LTs) occurs in human myeloid cells and B lymphocytes. However, the function of leukotrienes in B lymphocytes is unclear. Here, we report that B-cell chronic lymphocytic leukemia (B-CLL) cells produce leukotriene B4, and that specific leukotriene biosynthesis inhibitors counteracted CD40-dependent activation of B-CLL cells. Studies on the expression of the high-affinity receptor for LTB4 (BLT1) by flow cytometry analysis showed that the receptor was expressed, to a varying degree, in all investigated B-CLL clones. At a concentration of 100 nM, the drugs BWA4C (a specific 5-lipoxygenase inhibitor) and MK-886 (a specific 5-lipoxygenase activating protein inhibitor) markedly inhibited CD40-induced DNA synthesis (45% and 38%, respectively) and CD40-induced expression of CD23, CD54, and CD150. Addition of exogenous LTB4 (150 nM) almost completely reversed the effect of the inhibitors on DNA synthesis and antigen expression. Taken together, the results of the present study suggest that leukotriene biosynthesis inhibitors may have a therapeutic role in B-CLL.
Collapse
Affiliation(s)
- Gudmundur Runarsson
- Department of Medicine, Microbiology and Tumor Biology Center, Karolinska Institutet, 17177 Stockholm, Sweden
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Sepulveda MA, Emelyanov AV, Birshtein BK. NF-κB and Oct-2 Synergize to Activate the Human 3′ Igh hs4 Enhancer in B Cells. THE JOURNAL OF IMMUNOLOGY 2004; 172:1054-64. [PMID: 14707079 DOI: 10.4049/jimmunol.172.2.1054] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
In B cells, the Igh gene locus contains several DNase I-hypersensitive (hs) sites with enhancer activity. These include the 3' Igh enhancers, which are located downstream of the Calpha gene(s) in both mouse and human. In vivo experiments have implicated murine 3' enhancers, hs3B and/or hs4, in class switching and somatic hypermutation. We previously reported that murine hs4 was regulated by NF-kappaB, octamer binding proteins, and Pax5 (B cell-specific activator protein). In this study we report that human hs4 is regulated differently. EMSAs and Western analysis of normal B cells before and after stimulation with anti-IgM plus anti-CD40 showed the same complex binding pattern formed by NF-kappaB, Oct-1, and Oct-2 (but not by Pax5). A similar EMSA pattern was detected in mature human B cell lines (BL-2, Ramos, and HS-Sultan) and in diffuse large B cell lymphoma cell lines, although yin yang 1 protein (YY1) binding was also observed. We have confirmed the in vivo association of these transcription factors with hs4 in B cells by chromatin immunoprecipitation assays. The diffuse large B cell lymphoma cell lines had a distinctive slow-migrating complex containing YY1 associated with Rel-B. We have confirmed by endogenous coimmunoprecipitation an association of YY1 with Rel-B, but not with other NF-kappaB family members. Transient transfection assays showed robust hs4 enhancer activity in the mature B cell lines, which was dependent on synergistic interactions between NF-kappaB and octamer binding proteins. In addition, human hs4 enhancer activity required Oct-2 and correlated with expression of Oct coactivator from B cells (OCA-B).
Collapse
Affiliation(s)
- Manuel A Sepulveda
- Department of Cell Biology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
| | | | | |
Collapse
|
7
|
Ciric B, Howe CL, Soldan MP, Warrington AE, Bieber AJ, Van Keulen V, Rodriguez M, Pease LR. Human monoclonal IgM antibody promotes CNS myelin repair independent of Fc function. Brain Pathol 2003; 13:608-16. [PMID: 14655764 PMCID: PMC8096021 DOI: 10.1111/j.1750-3639.2003.tb00489.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
The human monoclonal IgM antibody sHIgM22 and mouse IgM monoclonal antibody 94.03 bind to oligodendrocytes, induce calcium signals in cultured glial cells, and promote remyelination in mouse models of multiple sclerosis. In order to address the mechanisms employed by these antibodies to promote CNS repair, bivalent monomers, F(ab')2 fragments, and monovalent forms of these antibodies were investigated to determine whether they exhibit the same remyelinating potential as the intact IgMs. The two antibodies displayed different structural requirements for retention of function. Antibody sHIgM22 remained functional even when reduced to a bivalent F(ab')2 fragment, while disruption of the pentameric structure of antibody 94.03 destroyed its functional properties. Competition studies demonstrated that the two antibodies recognize different entities on the surface of glial cells. These results indicate that the constant region and pentameric structure of IgM is not always necessary for the stimulation of myelin repair, eliminating the requirement for IgM immune effector functions in this process. The ability of the antibodies to cross-link cell surface determinants on oligodendrocytes appears to be an essential aspect of the mechanism of cellular activation. The finding that two antibodies, which induce similar in vivo effects, bind to different structures, and have different cross-linking requirements suggests that activation of glial cells involves the rearrangement of a complex membrane compartment.
Collapse
Affiliation(s)
- Bogoljub Ciric
- Departments of Immunology, Mayo Medical and Graduate Schools, Mayo Clinic Rochester, Minn
| | - Charles L. Howe
- Neurology, and Mayo Medical and Graduate Schools, Mayo Clinic Rochester, Minn
| | - Mateo Paz Soldan
- Neurology, and Mayo Medical and Graduate Schools, Mayo Clinic Rochester, Minn
| | | | - Allan J. Bieber
- Neurology, and Mayo Medical and Graduate Schools, Mayo Clinic Rochester, Minn
- Program in Molecular Neuroscience, Mayo Medical and Graduate Schools, Mayo Clinic Rochester, Minn
| | - Virginia Van Keulen
- Departments of Immunology, Mayo Medical and Graduate Schools, Mayo Clinic Rochester, Minn
| | - Moses Rodriguez
- Departments of Immunology, Mayo Medical and Graduate Schools, Mayo Clinic Rochester, Minn
- Neurology, and Mayo Medical and Graduate Schools, Mayo Clinic Rochester, Minn
- Program in Molecular Neuroscience, Mayo Medical and Graduate Schools, Mayo Clinic Rochester, Minn
| | - Larry R. Pease
- Departments of Immunology, Mayo Medical and Graduate Schools, Mayo Clinic Rochester, Minn
| |
Collapse
|
8
|
Malmborg Hager AC, Ellmark P, Borrebaeck CAK, Furebring C. Affinity and epitope profiling of mouse anti-CD40 monoclonal antibodies. Scand J Immunol 2003; 57:517-24. [PMID: 12791089 DOI: 10.1046/j.1365-3083.2003.01271.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The CD40-CD40L interaction plays a critical role in both humoral and cellular immune responses and interfering antibodies have been suggested as an effective approach for the treatment of lymphomas and autoimmune diseases. In this study we have profiled a panel of mouse antihuman CD40 monoclonal antibodies (MoAbs), regarding their CD40 binding affinity and epitope-specificity relative to the CD40L binding in relation to their cellular activating potential. Despite a rather similar domain-recognition profile, the MoAbs blocked the CD40L binding to a varying degree, with MoAb 5C3 being the poorest inhibitor. There was no correlation between affinity and cellular activation potential. In contrast, a correlation between the ability to block CD40L-binding and activation potential could be seen. We believe that this analysis of several mouse anti-CD40 antibodies can be used to develop strategies for producing new human anti-CD40 antibodies that can more effectively induce or block B-cell proliferation.
Collapse
|
9
|
Ellmark P, Ottosson C, Borrebaeck CAK, Malmborg Hager AC, Furebring C. Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library. Immunology 2002; 106:456-63. [PMID: 12153507 PMCID: PMC1782749 DOI: 10.1046/j.1365-2567.2002.01473.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
CD40 plays a central regulatory role in the immune system and antibodies able to modulate CD40 signalling may consequently have a potential in immunotherapy, in particular for treatment of lymphomas and autoimmune disease like multiple sclerosis. As a first step to achieve this goal, we describe the selection and characterization of a novel set of fully human anti-CD40 antibody fragments (scFv) from a phage display library (n-CoDeR). In order to determine their biological potential, these antibody fragments have been analysed for their ability to promote B-cell activation, rescue from apoptosis and to block the CD40-CD40 ligand (CD40L) interaction. The selected cohort of human scFv could be subcategorized, each expressing a distinct functional signature. Thus scFv were generated that induced B-cell proliferation, rescued B cells from apoptosis and blocked the CD40-CD40L interaction to different extents. In particular, one of the scFv clones (F33) had the ability to abrogate completely this interaction. The epitope recognition patterns as well as individual rate constants were also determined and the affinity was shown to vary from low to high nanomolar range. In conclusion, this panel of human anti-CD40 scFv fragments displays a number of distinct properties, which may constitute a valuable source when evaluating candidates for in vivo trials.
Collapse
Affiliation(s)
- Peter Ellmark
- Department of Immunotechnology, Lund University, Lund, Sweden
| | | | | | | | | |
Collapse
|
10
|
Wagner AH, Gebauer M, Pollok-Kopp B, Hecker M. Cytokine-inducible CD40 expression in human endothelial cells is mediated by interferon regulatory factor-1. Blood 2002; 99:520-5. [PMID: 11781233 DOI: 10.1182/blood.v99.2.520] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Given the significance of CD40-CD40 ligand interactions in chronic inflammatory diseases including atherosclerosis, the transcriptional regulation of CD40 expression as a potential therapeutic target was investigated in human umbilical vein cultured endothelial cells. Exposure to interferon-gamma (IFN-gamma) plus tumor necrosis factor-alpha resulted in a marked synergistic de novo expression of CD40, which, according to electrophoretic mobility shift analysis, was attributable to activation of the transcription factors nuclear factor-kappaB (NF-kappaB), signal transducer and activator of transcription-1 (STAT-1), and interferon regulatory factor-1 (IRF-1). Subsequent time-course studies revealed that de novo synthesis of IRF-1 preceded that of CD40. Decoy oligodeoxynucleotide (ODN) neutralization of STAT-1 or IRF-1, but not of NF-kappaB, inhibited cytokine-stimulated CD40 expression by 60% at both the mRNA and protein levels, and this effect was mimicked by antisense ODN blockade of IRF-1 synthesis. In contrast, CD40 expression in response to IFN-gamma stimulation was sensitive to neutralization of STAT-1 only. These findings suggest that depending on the cytokine composition, CD40 expression in human endothelial cells under proinflammatory conditions is governed by STAT-1 either directly or indirectly through de novo synthesis of IRF-1. Moreover, decoy ODN neutralization of these transcription factors may provide a novel therapeutic option for interfering with CD40-CD40 ligand-mediated inflammatory responses in vivo.
Collapse
Affiliation(s)
- Andreas H Wagner
- Department of Cardiovascular Physiology, University of Goettingen, Germany
| | | | | | | |
Collapse
|
11
|
Glassford J, Holman M, Banerji L, Clayton E, Klaus GG, Turner M, Lam EW. Vav is required for cyclin D2 induction and proliferation of mouse B lymphocytes activated via the antigen Receptor. J Biol Chem 2001; 276:41040-8. [PMID: 11546804 DOI: 10.1074/jbc.m105305200] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
B lymphocytes from mice null for the Rho-family guanine-nucleotide exchange factor, Vav, are defective in their ability to proliferate in response to BCR cross-linking, but are able to proliferate normally in response to LPS. In addition, they have a depletion of CD5(+) (B1) lymphocytes and defective IgG class switching. This phenotype is reminiscent of that observed in mice null for the cell cycle regulatory protein, cyclin D2. We demonstrate here that the inability of vav(-/-) B cells to proliferate in response to BCR ligation is due to an inability to induce cyclin D2. In addition, we show that the proliferative defect of these cells occurs after the cells have entered early G1 phase. Analyses of potential down-stream signaling intermediates revealed differential activation of the stress-activated MAP kinases in the absence of Vav, normal activation of the ERK, MAPK, and phosphatidylinositol 3-kinase pathways, and defective intracellular calcium mobilization. We further demonstrate that intracellular calcium homeostasis is required for cyclin D2 induction, implicating a possible link with the defective calcium response of vav(-/-) B cells and their inability to induce cyclin D2.
Collapse
Affiliation(s)
- J Glassford
- Ludwig Institute for Cancer Research and Section of Virology and Cell Biology, Imperial College School of Medicine at St Mary's, Norfolk Place, London W2 1PG, United Kingdom
| | | | | | | | | | | | | |
Collapse
|